DRG Market Assessment reports

Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care…

The wet age-related macular degeneration (AMD) therapy market in the United States is unique given the dominance of Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD,…

The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…

Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…

Following the introduction of the anti-VEGF therapies over a decade ago, the wet AMDmarket has been dominated by three therapies—Roche/Genentech/Novartis’s Lucentis, approved for wet AMD,…

In late age-related macular degeneration (AMD), vision deficits are noticeable, are often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (…

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the United States and Europe. The majority of patients with advanced AMD have the wet form of the…

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued…

Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. Use of off-label…

Last Updated 30 December 2015 In late age-related macular degeneration (AMD), vision deficits are noticeable, often debilitating, and can be a precursor to blindness. The availability of vascular…

TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2015 (EU) is the fourth annual syndicated report that offers a snapshot of dry and wet age-related macular degeneration (AMD) market…

Wet age-related macular degeneration (AMD) is characterized by abnormal growth of blood vessels under the retina, leading to optic nerve damage, visual impairment, and potentially blindness…